BJMO - volume 12, issue 4, august 2018
P. Specenier MD, PhD
This article will summarize the key data in the field of head and neck cancer presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Read moreBJMO - volume 12, issue 4, august 2018
F.P. Duhoux MD, PhD
At ASCO 2018, the results of several anticipated studies were presented. While most of these studies were thought provoking, many results left practicing oncologists a little bit disoriented. How to translate these data in clinical practice?
Read moreBJMO - volume 12, issue 4, august 2018
M. Rasschaert MD, L. Triest MD, J. Van den Brande MD, K. Papadimitriou MD, PhD, H. Prenen MD, PhD, M. Peeters MD, PhD
The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.
Read moreBJMO - volume 12, issue 4, august 2018
T. Vermassen PhD, S. Rottey MD, PhD
From June 1st till June 5th, Chicago was host for the 54th ASCO annual meeting. The theme for this year’s venue was ‘Delivering Discoveries: Expanding the Reach of Precision Medicine’. With more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field; this year’s meeting was a great success. This report will highlight 11 key studies concerning genitourinary cancers presented during the meeting.
Read moreBJMO - volume 12, issue 4, august 2018
B. Neyns MD, PhD, G. Awada MD, J. K. Schwarze
This article will summarize the key data in the field of immunotherapy presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Read moreBJMO - volume 12, issue 4, august 2018
Tom Feys MBA, MSc
The melanoma highlights from ASCO 2018 include data on the surgical management of sentinel lymph node (SLN) positive melanoma, updated results from the Checkmate 238 study evaluating adjuvant nivolumab or ipilimumab for resected stage III and IV melanoma, the overall survival (OS) data of the COLUMBUS trial assessing the combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib in the treatment of unresectable BRAF-mutant melanoma and two studies evaluating immunotherapy for unresectable Merkel cell carcinoma. For a more complete overview of melanoma data presented at ASCO 2018 please refer to the official congress website (www.am.asco.org).
Read moreBJMO - volume 12, issue 3, may 2018
W. Lybaert MD, I. Dero MD, M. Peeters MD, PhD
With the background of the famous Golden Gate Bridge and Alcatraz, the annual Gastrointestinal Cancers Symposium was held from 18–20 January 2018 in the Moscone Congress Center in San Francisco, California. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2018:12(3):133–141)
Read more
Top
